- Home
- CRDF vs TCRX Comparison
CRDF vs TCRX Comparison
Compare CRDF & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- TCRX
- Stock Information
- Founded
- CRDF 1999
- TCRX 2018
- Country
- CRDF United States
- TCRX United States
- Employees
- CRDF N/A
- TCRX N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- CRDF Health Care
- TCRX Health Care
- Exchange
- CRDF Nasdaq
- TCRX Nasdaq
- Market Cap
- CRDF 144.4M
- TCRX 123.7M
- IPO Year
- CRDF N/A
- TCRX 2021
- Fundamental
- Price
- CRDF $2.20
- TCRX $2.05
- Analyst Decision
- CRDF Strong Buy
- TCRX Strong Buy
- Analyst Count
- CRDF 5
- TCRX 5
- Target Price
- CRDF $11.10
- TCRX $9.40
- AVG Volume (30 Days)
- CRDF 762.3K
- TCRX 452.8K
- Earning Date
- CRDF 11-06-2025
- TCRX 11-11-2025
- Dividend Yield
- CRDF N/A
- TCRX N/A
- EPS Growth
- CRDF N/A
- TCRX N/A
- EPS
- CRDF N/A
- TCRX N/A
- Revenue
- CRDF $545,000.00
- TCRX $6,961,000.00
- Revenue This Year
- CRDF N/A
- TCRX $255.18
- Revenue Next Year
- CRDF N/A
- TCRX N/A
- P/E Ratio
- CRDF N/A
- TCRX N/A
- Revenue Growth
- CRDF N/A
- TCRX N/A
- 52 Week Low
- CRDF $1.90
- TCRX $1.02
- 52 Week High
- CRDF $5.64
- TCRX $6.23
- Technical
- Relative Strength Index (RSI)
- CRDF 52.58
- TCRX 59.59
- Support Level
- CRDF $1.99
- TCRX $1.70
- Resistance Level
- CRDF $2.13
- TCRX $2.40
- Average True Range (ATR)
- CRDF 0.10
- TCRX 0.16
- MACD
- CRDF 0.04
- TCRX 0.04
- Stochastic Oscillator
- CRDF 78.69
- TCRX 56.25
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.